Sabitlenmiş Tweet
We had a great time leading the Clinical Session at RPA 2026 today @NephroShah. Thank you @KatieKwonMD for inviting us and @brian_rifkin for leading with #NephJC content creation.
English
Gates Colbert, MD
2.2K posts
Gates Colbert, MD
@DoctorGates
Nephrologist & AHSCP Hypertension Specialist. BUMC Nephrology Co-PD. Active in Healthcare Advocacy, Research, and Kidney Care. #NephJC #NSMC
Dallas, Texas Katılım Haziran 2011
416 Takip Edilen1.6K Takipçiler
We are in a sports draught withdrawal in the 🇺🇸 . Football get here soon @dallascowboys @OU_Football @DallasStars
English
Gates Colbert, MD retweetledi
Join us for the 51st Annual DCMS Physician & Student Mixer on Saturday, August 15, 2026, an evening dedicated to connection, mentorship, and inspiring the next generation of physicians. Get more info at na2.hubs.ly/H06M_Fz0
English
@brian_rifkin @JonathanNefro If a patient is willing to stick to a regimen, they are less likely to be caught in a situation that leads to hospitalization. Not clear the SGLT2i is the actual difference maker.
English
@JonathanNefro SGLT transporters are located all over the body, but mechanistically how is this possible?!
English
Con un trastorno psiquiátrico (depresión, bipolaridad o esquizofrenia) consumir iSGLT2, comparado a no hacerlo; se asoció a ↓39% el riesgo de desarrollar demencia y ↓20% de hospitalización psiquiátrica
JAMA Network Open 2026
10.1001/jamanetworkopen.2026.19985
Español
English
Congratulations Vera Therapeutics on your provisional approval of atacicept for the treatment of high risk IgA nephropathy. Now available as TRUTAKNA.
The ORIGIN phase 3 trial was covered by @NephJC here: nephjc.com/news/atacicept…
and as discussed on @FreelyFiltered here: nephjc.com/freelyfiltered…
English
@brendonneuen ASI class are the solution and we are living in 2030 now?
English
Fascinating, hypothesis generating data from MRA trials in HF, suggesting that (1) low dose MRA incompletely block MR activity, (2) there are differential effects on aldo based on pre-treatment levels, and (3) effects on outcomes are modified by BL aldo
doi.org/10.1093/eurhea…
English
@brian_rifkin @NephRodby @AgarwalRajivMD I would offer for consideration that some of the existing classes of medications simply do nothing for many individuals. We are a mosaic of responders and non responders. Given the existing drug classes, we have not solved and cured hypertension. We must look for more options.
English
@NephRodby @AgarwalRajivMD Great to have new 💊💉 & therapies, but do you really think most uncontrolled BP is due to a lack of choices? Cost, convenience, compliances and a patient’s focus & understanding of long-term outcomes go a lot further toward attaining goals.
PS What % of CKD pts are on ACEi/ARB?
GIF
English
Hypertension is at an inflection point.
For years we framed it as a tradeoff: push everyone to a lower number, OR tailor therapy to the patient.
That tradeoff is dissolving. We can now do both. Here's why.
English
@eric_weinhandl Shocked ASN was invited to the party (sarcasm). We usually get left out.
English
New guideline alert.
2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | JACC jacc.org/doi/10.1016/j.…
English
@ZachJonesForTX I want more flyovers. Double the jets. Add a helicopter. Add a plane the giant sign behind it. Blimp too.
English
@brian_rifkin The anti-ACEI. Reputation of SGLT2is keep building. And now $15 for 90 days
English
SGLT2i, anemia and CV outcomes #ERA26
📈Hgb increase 0.6-0.8 g/dL
Is it just hemoconcentration?
🩸No, saw increased retics/erythrocytes
🤔⬆️ H/H were strongest markers for benefits from SGLT2i
English
@edgarvlermamd @NEJM @HeerspinkHiddo @AgarwalRajivMD @brendonneuen @KatherineTuttl8 @VladoPerkovic @ChristophWanne4 @ERAkidney It’s also interesting to see the “ho-hum” reception on Nephtwitter. Are we getting spoiled ?
English
FIND-CKD: Among adults with CKD who did not have diabetes, finerenone led to a slower decrease in the eGFR than placebo over 32 months ca. 2026 from @NEJM #Nephpearls #ERA26 🏴
👉 nejm.org/doi/full/10.10…
Edgar V. Lerma 🇵🇭@edgarvlermamd
@drjitendergupta @mvaduganathan @brendonneuen @RangaswJ @NDTsocial FIND-CKD: Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with “Non-Diabetic” CKD randomized trial ca. 2024 from @NDTsocial #Nephpearls #Cardiorenal 👉🏼 pubmed.ncbi.nlm.nih.gov/38858818/
Riverside, IL 🇺🇸 English
@eric_weinhandl @GrahamAbra True in terms boldness. But so many patients can’t tolerate spironolactone, or refuse to try lower doses after side effects appear. Gentler finerenone will result in less pronounced data as the molecule hits different targets
English
Totally awesome but in a sign of how blessed we have been with positive trials the last few years I’m a little underwhelmed
Low risk group of ESKD in the near term enrolled, tough to show reduction in need for dialysis
NEJM@NEJM
Presented at #ERA26: In adults without diabetes who had chronic kidney disease, the nonsteroidal mineralocorticoid receptor antagonist finerenone led to a slower decrease in the estimate glomerular filtration rate than placebo over 32 months. Full phase 3 FIND-CKD trial results: nej.md/4wWOFV4 @ERAkidney
English
English
I clearly missed the memo!
RIP Diabetes Insipidus
AVP-R (nephrogenic DI)
AVP-D (central DI)
cmaj.ca/content/198/18…
cc @NephRodby @kidney_boy - guess you guys knew this?
English
@michaelturk6 @michaelturk6 after reading the latest AJKD for May, I think I agree with you. Could do one oral treatment and Rituximab 2x per year
English
I have a 25 yo M with Minimal Change Disease and egr 100, but UPC 2.9 g. He does not want a complicated regimen and likely will only commit to 1 pill per
day. What are you choosing ?
English
Gates Colbert, MD retweetledi
Hypertension and CKD ca. 2026 from @indianjnephrol @DoctorGates @AnnaGaddy @AnandhUrmila
#Nephpearls
👉 indianjnephrol.org/current-issue/
English
@kidney_boy It’s incredible news for patients! The loss of medical directorships and JV partnerships for nephrology practices will become a real workforce issue as an unintended result. @RPANephrology
English
I overheard this morning that Fresenius closed 100 dialysis units in the US last quarter.
Decades of progress in CKD is starting to show progress
English
@collazor1 Glad to see another option. But 7 tabs is a lot to consume daily. All while on fluid restrictions 😬
English
Gates Colbert, MD retweetledi
@NephroSeeker @DrAkshayaJ #RPA26 #NephJC
GLP1 tidal wave 2005-2025
FLOW = improved MAKE endpoints
Mechanisms remain uncertain (but they work 🤷)
REMODEL AND SURPASS CVOT may elucidate this further
Orals are now available (no CKD indication yet)
@DoctorGates
English